Business Wire

Canadian Credit Union Extends Partnership with Temenos and Harnesses the Power of Data to Drive Growth

Share

Temenos (SIX: TEMN), the banking software company, today announced that Salmon Arm Savings and Credit Union (SASCU) has extended its long-standing relationship with Temenos, completing an implementation of the newest functionality of Temenos Analytics to drive its growth strategy. With 20,000 members, and $800 million assets under management, SASCU continues to grow in size and product offerings, using Temenos Analytics to deliver seamless, hyper-personalized digital experiences for its members.

According to a recent report by the Economist Intelligence Unit, improving the account holder experience and engagement is the top strategic priority for financial institutions around the world. SASCU is a forward-looking, community-focused, financial organization driven to provide world-class products and services for all phases of a member’s life. Recognizing the power of data, SASCU has been using Temenos Analytics to drive profitability and strategy for 10+ years as it has grown. Focused on attracting and retaining members, and expanding wallet share through an outstanding experience, SASCU is one of the top performing credit unions in Canada.

Temenos Services Partner ClearSight Solutions collaborated with Temenos to implement additional capabilities at the credit union to modernize the way SASCU uses data with Temenos’ industry-leading funds transfer pricing and activity-based costing capabilities. Leveraging the full strength of Temenos’ powerful reporting tools, SASCU can now calculate the profitability of every member and product using industry best practice financial models in order to identify areas for improvement and new product development. This will enable the credit union to improve financial performance and the member experience.

Over the past five years, online banking visits have nearly doubled. A seamless digital member experience is vital to SASCU’s member acquisition and retention goals. Temenos Analytics is core-agnostic, allowing SASCU to run on a third-party core, break down data silos and improve data accuracy, all with a single view.

Barry Delaney, President and Chief Financial Officer, SASCU Financial Group, commented: “Our vision is to be our members’ lifelong partner – to do that, we need to make sure that we are offering them the products and services they need. Advice and member experience is not one-size-fits-all. We continuously seek new ways of doing things, and for that we need to fully leverage our data. Temenos has enabled us to enhance the range of products we offer in order to deliver better choice, value, and a member-centric experience. By expanding our relationship with Temenos and implementing the enhanced functionality, we will empower our employees to better serve our members, and fully leverage data to drive our strategy.”

Jacqueline White, President, Americas, Temenos, said: “Financial institutions face many challenges such as the acceleration of digital, intense competition, changing account holder behavior, and high operating costs. Continued investment in innovation and technology is vital to success, which is why more than 30 Canadian banks and credit unions partner with Temenos. As a leading provider of banking technology, Temenos enables SASCU to overcome these challenges and create hyper-personalized experiences, ensure higher member satisfaction and increase profits. We’re delighted that, supported by ClearSight’s valuable in-depth business and technical knowledge, SASCU has implemented additional Temenos technology, and we look forward to continuing to support the team as it continues to grow and create meaningful member relationships.”

Michael Zywicki, Partner, ClearSight Solutions, added: “By deploying Temenos Analytics, SASCU demonstrates its understanding that modern tools and data are required to better understand members’ activities and relationship value. ClearSight is excited to be part of this project and to see how SASCU uses the enhanced knowledge of their members to provide them with a differentiated experience.”

– Ends –

About SASCU

SASCU Financial Group offers a broad range of personal and business financial services through SASCU Credit Union and its three lines of business, SASCU Insurance, SASCU Wealth and Commercial banking. SASCU Credit Union branches are in Sicamous and Sorrento, plus two in Salmon Arm. Insurance offices are located in Salmon Arm and Enderby. Established in 1946, SASCU has more than 19,000 members, 150 staff and $900 million in assets. In addition, SASCU stewards $235 million in client investments and serves more than 5000 insurance customers. Learn more at sascu.com.

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business. For more information, please visit www.temenos.com.

About ClearSight

ClearSight Solutions is a Canadian headquartered company with offices in Vancouver, Canada, London, UK and San Jose, Costa Rica whose sole purpose is giving customers the best experience and service they deserve.

As a Temenos Partner, ClearSight provides expert services to deliver on premise or cloud-based data and analytics products. Our mission is to work with customers throughout their data and analytics journey to drive maximum value from their data and analytic investments.

Contact information

Media

Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com

Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 202123.4.2021 17:05:00 EEST | Press release

LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Results were shared as an oral presentation during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021. Tralokinumab is a high affinity, human monoclonal antibody that specifically binds to and inhibits the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.2,3 It is an investigational therapy in clinical development, and its safety and efficacy are currently being evaluated by regulatory authorities. The interim analysis at 56 weeks in the ECZTEND trial (NCT03587805) showed tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) demonstrated long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms.1 Patients who had enrolled in pivotal Phase 3 trials ECZTRA 1 and 2 who continued into ECZTEND w

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic23.4.2021 16:11:00 EEST | Press release

Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine tablets), which may contribute to their ability to fight infections and develop protective antibodies from vaccines. The data were presented at the 2021 American Academy of Neurology (AAN) Annual Meeting that was held virtually 17-22 April 2021. In the MAGNIFY-MS study, reduction of memory B cells occurred as early as one month after MAVENCLAD initiation with lowest levels sustained for up to 12 months, while naïve B cells, which are typically required for the generation of antibody responses following vaccination, began recovering immediately. Previously shared data from MAGNIFY-MS indicated that patients receiving MAVENCLAD are able to mount responses to influenza and varicella zoster vaccines, irrespec

Xsolla Offers Exit Strategies to Game Studios for Exit Advising and Planning23.4.2021 16:00:00 EEST | Press release

Xsolla, the video game commerce company powered by its Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, has announced Xsolla Exit Strategies. The new service will connect development studios with financial and transaction advisors, guiding them through the process of selling their game property or studio, from due diligence preparation to exiting. The unveil of Xsolla Exit Strategies comes full circle from Xsolla Funding Club, launched March 2019, which provides matchmaking between vetted game projects and qualified investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005013/en/ Let Xsolla Exit Strategies match you with a financial and transaction advisor to help meet your exit goals. (Graphic: Business Wire) The gaming industry continues to flourish as demand is high for strategic partnerships and acquisitions for both game companies

Wipro Achieves Google Cloud Partner Specialization in Application Development23.4.2021 15:33:00 EEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has achieved the Google Cloud Partner Specialization in application development. This marks the fourth Partner Specialization badge that Wipro has received from Google Cloud, following recognition for outstanding cloud security, migration, and work transformation. This specialization demonstrates Wipro’s capabilities across multiple areas as a Google Cloud SI partner. As a trusted Google Cloud partner, Wipro can help customers leverage the best of Google Cloud platform as they develop and manage cloud-native business applications, enabling faster time to market, increasing scalability of applications and integrating them with external and internal systems in the IT landscape. This specialization will allow Wipro’s team of certified professionals to accelerate the customer modernization journey, increase agility and adapta

LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis23.4.2021 14:59:00 EEST | Press release

LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The CHMP positive opinion is one of the final steps before the European Commission makes its decision on the Marketing Authorization Application for use of Adtralza, an investigational therapy in clinical development, throughout the European Union. This final decision is expected in the coming months and if authorized, Adtralza will be the first fully human, monoclonal antibody available to specifically target the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms. Adtralza specifically targets IL-13 with high affinity and is developed to improve the symptoms of atopic derma

Schlumberger Announces First-Quarter 2021 Results23.4.2021 13:50:00 EEST | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the first-quarter 2021. First-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31, 2021 Dec. 31, 2020 Mar. 31, 2020 Sequential Year-on-year Revenue* $5,223 $5,532 $7,455 -6% -30% Income (loss) before taxes - GAAP basis $386 $471 $(8,089) -18% n/m Net income (loss) - GAAP basis $299 $374 $(7,376) -20% n/m Diluted EPS (loss per share) - GAAP basis $0.21 $0.27 $(5.32) -22% n/m Adjusted EBITDA** $1,049 $1,112 $1,347 -6% -22% Adjusted EBITDA margin** 20.1% 20.1% 18.1% 0 bps 203 bps Pretax segment operating income** $664 $654 $776 1% -14% Pretax segment operating margin** 12.7% 11.8% 10.4% 88 bps 230 bps Net income, excluding charges & credits** $299 $309 $351 -3% -15% Diluted EPS, excluding charges & credits** $0.21 $0.22 $0.25 -5% -16% Revenue by Geography International $4,211 $4,343 $5,225 -3% -19% North America* 972 1,167 2,180 -17% -55% Other 40 22 50 n/m n/m $5,223 $5,532 $7,455 -6%

ANAORI kakugama: The New Cooking Tool Shaking Up the Culinary World23.4.2021 13:30:00 EEST | Press release

Japanese brand ANAORI, a leader in manufacturing carbon graphite products, has developed a groundbreaking cooking tool that combines new technologies and natural materials in a unique design. In the coming weeks, renowned chefs from around the world will apply their expertise to showcase the potential of ANAORI kakugama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005016/en/ ANAORI kakugama Watch the ANAORI kakugama video here ANAORI kakugama: The Culinary Tool Combining Tradition and Innovation The philosophy of ANAORI was born out of respect for Japanese culture, rooted in a tradition of living in harmony with nature. Naturality according to ANAORI means understanding the principles of nature without confronting it, multiplying its powers by means of minimal intervention, in order to best utilise it. The Japanese company unveils two ANAORI kakugama models in two different sizes, to cook with the rhythm of the seas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom